Jump Financial LLC Takes $452,000 Position in Kura Oncology, Inc. (NASDAQ:KURA)

Jump Financial LLC bought a new stake in shares of Kura Oncology, Inc. (NASDAQ:KURAFree Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 49,614 shares of the company’s stock, valued at approximately $452,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of KURA. Raymond James & Associates lifted its stake in Kura Oncology by 18.6% in the 1st quarter. Raymond James & Associates now owns 17,598 shares of the company’s stock valued at $283,000 after buying an additional 2,757 shares in the last quarter. MetLife Investment Management LLC lifted its stake in Kura Oncology by 47.3% in the 1st quarter. MetLife Investment Management LLC now owns 34,950 shares of the company’s stock valued at $562,000 after buying an additional 11,227 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Kura Oncology by 38.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,070,685 shares of the company’s stock valued at $17,217,000 after buying an additional 296,175 shares in the last quarter. Vanguard Group Inc. lifted its stake in Kura Oncology by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 3,330,346 shares of the company’s stock valued at $53,553,000 after buying an additional 56,638 shares in the last quarter. Finally, Bridgefront Capital LLC purchased a new position in Kura Oncology in the 1st quarter worth approximately $180,000.

Insider Transactions at Kura Oncology

In related news, CEO Troy Edward Wilson sold 91,052 shares of the business’s stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $20.23, for a total value of $1,841,981.96. Following the completion of the sale, the chief executive officer now directly owns 559 shares of the company’s stock, valued at $11,308.57. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CEO Troy Edward Wilson sold 91,052 shares of the business’s stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $20.23, for a total value of $1,841,981.96. Following the completion of the sale, the chief executive officer now directly owns 559 shares of the company’s stock, valued at $11,308.57. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Kathleen Ford sold 1,496 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $17.80, for a total transaction of $26,628.80. Following the completion of the sale, the chief operating officer now directly owns 21,602 shares of the company’s stock, valued at $384,515.60. The disclosure for this sale can be found here. In the last three months, insiders sold 96,919 shares of company stock valued at $1,946,415. Insiders own 5.40% of the company’s stock.

Kura Oncology Price Performance

Kura Oncology stock opened at $19.97 on Friday. The stock has a market cap of $1.48 billion, a P/E ratio of -9.89 and a beta of 0.85. The company has a fifty day simple moving average of $15.21 and a 200-day simple moving average of $11.47. Kura Oncology, Inc. has a 12-month low of $7.41 and a 12-month high of $22.92. The company has a current ratio of 16.71, a quick ratio of 16.71 and a debt-to-equity ratio of 0.02.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on KURA shares. Mizuho started coverage on shares of Kura Oncology in a research note on Friday, December 22nd. They issued a “buy” rating and a $26.00 target price on the stock. Wedbush decreased their target price on shares of Kura Oncology from $40.00 to $37.00 and set an “outperform” rating on the stock in a research note on Friday, November 3rd. JMP Securities raised their target price on shares of Kura Oncology from $22.00 to $32.00 and gave the stock a “market outperform” rating in a research note on Wednesday, January 31st. HC Wainwright reissued a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a research note on Friday, December 8th. Finally, StockNews.com raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Thursday, February 1st. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $28.28.

View Our Latest Stock Report on KURA

Kura Oncology Company Profile

(Free Report)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications.

Read More

Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURAFree Report).

Institutional Ownership by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.